NCT02662127

Brief Summary

Venous disease effects 25% of the population and most healthy people experience venous symptoms after standing for too long. The prime function of leg veins is drainage. Failure leads to a condition called chronic venous insufficiency (CVI) with leg pain, heaviness, swelling, varicose veins, ankle skin changes, eczema and occasionally venous ulcers. The aim of the study is to identify blood components (biomarkers) that occur during the damaging phase of standing versus the healing phases of lying recovery and with medical compression stockings. This will be achieved by taking a blood sample from the ankle region at 3 separate visits (days) to the vascular laboratory at Ealing Hospital. The first visit will be after supervised standing for 1 hour. The second after supervised lying and the third standing whilst wearing a medical compression stocking. Healthy volunteers will be compared to patients with advanced CVI. The potential importance to patients and the public is threefold. Firstly, biomarker profiles will be obtained in each of the 3 states to increase understanding in the cellular mechanisms of damage and recovery. In this way "bad" and "good" biomarkers can be identified. Secondly, drug treatments may develop from this research to adjust biomarkers towards a favourable profile. Thirdly, the success of treating CVI with surgery, venous intervention or compression can be monitored. Whilst it is known that relief of gravitational stress is the treatment for all forms of CVI, the mechanisms of repair and its discrimination from damage have yet to be identified.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
31

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2016

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 13, 2016

Completed
12 days until next milestone

First Posted

Study publicly available on registry

January 25, 2016

Completed
2 months until next milestone

Study Start

First participant enrolled

April 1, 2016

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2017

Completed
Last Updated

April 12, 2017

Status Verified

April 1, 2017

Enrollment Period

1.2 years

First QC Date

January 13, 2016

Last Update Submit

April 10, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of biomarkers which decrease greater than 20% of the baseline level as a result of the interventions of (i) lying down and with a (ii) stocking

    1 year

Study Arms (1)

SIGVARIS®. Class 2 - RAL: 23-32

EXPERIMENTAL

Graduated elastic compression stockings

Device: SIGVARIS® Class 2 - RAL: 23-32.

Interventions

Below knee graduated elastic compression stocking

SIGVARIS®. Class 2 - RAL: 23-32

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients from the vascular clinic at Ealing Hospital with venous disease
  • Venous skin changes including lipodermatosclerosis and pigmentation
  • Significant reflux \>0.5 seconds on duplex
  • Volunteers from NHS healthcare workers or the general public
  • Absence of venous symptoms
  • Freedom from varicose veins or skin changes

You may not qualify if:

  • Previous treatment for varicose veins on the study leg
  • Previous history of deep or superficial vein thrombosis
  • Receiving anticoagulation
  • Haematological disorders of coagulation or thrombosis
  • Pregnancy
  • Significant peripheral vascular disease
  • Cardiac failure or orthopnoea
  • Uncontrolled/active malignancy
  • Significant impairment of mobility
  • Connective tissue or autoimmune disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ealing Hospital, LNWH NHS Trust

Ealing, UB1 3HW, United Kingdom

RECRUITING

Study Officials

  • Evi Kalodiki, MD PhD FRCS

    London North West Healthcare NHS Trust

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Christopher R Lattimer, MBBS FRCS MS FdIT PhD

CONTACT

Evi Kalodiki, MD PhD FRCS

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 13, 2016

First Posted

January 25, 2016

Study Start

April 1, 2016

Primary Completion

July 1, 2017

Study Completion

July 1, 2017

Last Updated

April 12, 2017

Record last verified: 2017-04

Data Sharing

IPD Sharing
Will not share

Locations